Reply  by Meune, Christophe & Duboc, Denis
REPLY
We thank Drs. Stöllberger and Finsterer for their comments about
our paper (1). They point out several questions, indicating that
they probably do not adhere to our conclusion of a preventive effect
of perindopril in children with Duchenne muscular dystrophy. The
main limitation may be the apparent delay of 60 months to observe
a benefit of therapeutics.
In fact, this trial investigated a preventive effect very early in the
course of Duchenne disease (mean age of children 10.6 years with
normal left ventricular ejection fraction [LVEF]); as a conse-
quence, LVEF was preserved at 36 months. These children
probably have cardiac involvement that is not accurately detected
by conventional measurements; more sensitive methods might be
useful in this setting (2). Conversely, after 60 months’ total
follow-up, children were older (mean age 15.6 years) and cardiac
deterioration could be demonstrated in the group receiving placebo
during phase 1; this is in accordance with the natural course of the
disease. Such degradation in LVEF is representative of the
ineluctable course of the disease, and it was not accurately
prevented by a delayed initiation of perindopril. As 1) groups were
comparable for demographics, cardiac status, respiratory and pe-
ripheral muscle function, 2) drug allocation (placebo or perindo-
pril) during phase 1 was the only difference, thus the natural
conclusion is that five years of perindopril may delay the onset and
progression of LV dysfunction when compared to later and shorter
initiation. The trend in lower mortality in the perindopril group
reinforces our conclusion.
All adverse effects mentioned in our study were present during
the first phase of the study, with no difference between placebo
group or perindopril group.
Patients with and without LVEF dysfunction at the end of the
protocol had similar baseline values (64.9 6.5% vs. 65.0 5.4%,
respectively, p  NS).
No patient had significant increased LVEF during the study.
Mean LVEF declined moderately in both groups, and some
patients exhibited more severe degradation, which reflects hetero-
geneity in the course of the disease.
In our study, radionuclide ventriculography was chosen to
determine LVEF, as it is the “gold standard” method. The
measurement of LVEF is a direct count of radionuclide activity.
Conversely, LVEF determined by echocardiography needs a
mathematical hypothesis that may not be valid in cases of severe
thoracic deformation (3). Finally, patients with Duchenne disease
very frequently have poor quality of acoustic echocardiographic
windows.
This study was focused on a possible preventive effect of
perindopril on LVEF, which is an important prognosis factor,
contrary to electrocardiograms, ventricular arrhythmias, and late
potential signal-average (4).
In conclusion, this correspondence illustrates the need for
simple and adequate methodology to limit misinterpretation of
investigative results, integrating the difficulties of such necessary
controlled trials conducted in a rare disease.
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Concomitant Surgical
Myocardial Revascularization Is
Still the Gold Standard for Combined
Valvular and Coronary Heart Disease
We read with great interest the study by Byrne et al. (1). This
study claims percutaneous intervention before valve surgery is a
safe approach compared to standard surgical revascularization
concomitantly with valve surgery. We believe the investigators’
conclusions are extrapolated and incorrect based on nonsignificant
scientific facts along with a study design that has insufficient power
to support their findings.
First, the primary objectives were not clearly defined, as the
researchers want to show the relative advantage of angioplasty over
standard combined surgery. To demonstrate a difference in mor-
tality, risk of bleeding, or number of tranfusions, one has to make
a clear hypothesis and harbor a strict scientific methodology and
study design. A retrospective analysis of a single-center heteroge-
neous group of patients (12 men and 14 women between 53 and 91
years of age) cannot scientifically conclude due to an unclear
hypothesis.
Second, the mean time to angioplasty does not respect the
recommendations accepted by the general scientific community,
which should be 4 to 6 h. Only three patients had their interven-
tion done limit the critical edge of 6 h (3 on 26; 11%).
The control group that was used to demonstrate a difference in
mortality is inadequate. Comparison of 26 heterogeneous patients
with a historical cohort of 100,000 patients introduces a funda-
mental bias. The calculated predicted mortality of 22% represents
the median produced from a complex mathematical algorithm of a
stratified risk ranging from 3.5% to 63.5%. From our standpoint,
the comparison of the study group based on this extrapolated risk
is questionable. Despite a mortality of 3.8% for the presented
population (1 of 26 patients), the difference is not statistically
significant (p 0.05) and therefore the general conclusions cannot
be supported. Finally, the survival curve at 36 months included
fewer than 10 patients. Because this study seemed to be initially
designed to look at the 30-day mortality, this portion of the curve
is not interpretable.
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